REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium
REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Wall Street Analysts Think Regenxbio (RGNX) Could Surge 234.37%: Read This Before Placing a Bet
RegenXBio Grants RSUs to Executives Amidst Leadership Transition
Barclays Maintains Overweight on Regenxbio, Lowers Price Target to $50
Regenxbio Analyst Ratings
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Raises Target Price to $39
Express News | Regenxbio Inc. : H.c. Wainwright Raises Target Price to $39 From $38
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $50
Buy Rating Affirmed for RegenXBio on Strong Clinical Updates and Strategic FDA Engagements
Analysts Are Bullish on Top Healthcare Stocks: Twist Bioscience (TWST), RegenXBio (RGNX)
REGENXBIO Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Earnings Call: REGENXBIO Reports Progress in Gene Therapy Programs
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), RegenXBio (RGNX) and Laboratory (LH)
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $40
Express News | Regenxbio Inc : BofA Global Research Cuts Price Objective to $28 From $33
Express News | Regenxbio Inc : Barclays Cuts Target Price to $50 From $55
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $35
RBC Capital Sticks to Their Buy Rating for RegenXBio (RGNX)
Express News | Regenxbio Inc : Leerink Partners Cuts Target Price to $34 From $35